Xefocam, pills 8 mg 30 pcs.

Composition

1 tablet contains lornoxicam 8 mg

. Pharmacological action

XEFOCAM is an NSAID of the oxycam class; it has anti-inflammatory, analgesic, antipyretic and antiplatelet effects.

Inhibits pro-inflammatory factors, reduces platelet aggregation; inhibits COX 1 and COX 2, disrupts arachidonic acid metabolism, reduces Pg production both in the inflammatory focus and in healthy tissues; suppresses the exudative and proliferative phases of inflammation.

Indications

Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, joint syndrome with gout exacerbation, bursitis, tendovaginitis.

Pain syndrome (mild to moderate intensity): arthralgia, myalgia, neuralgia, lumbago, sciatica, migraine, tooth and headache, algodismenorrhea, pain from injuries, burns.

Febrile syndrome (“colds” and infectious diseases).

Contraindications

• Known hypersensitivity/allergic to lornoxicam or one of the components of Xefocam;
• specifying a history of hypersensitivity to acetylsalicylic acid or other NSAIDs;
• bleeding diathesis or coagulation failure, and surgery was associated with a risk of bleeding or incomplete hemostasis;
• ulcer disease of stomach and duodenum in the acute phase;
• ulcerative colitis;
• severe disturbances of liver function;
• moderate to severe renal dysfunction (serum creatinine >300 µmol/l);
• hypovolaemia or dehydration;
• confirmed or suspected bleeding in the brain;
• bronchial asthma;
• heart failure;
• hearing loss;
• deficiency of glucose-6-phosphate dehydrogenase;
• pregnancy;
• lactation;
• children up to age 18 years.
• With caution:
• arterial hypertension;
• anemia.

Side effects

From the digestive tract and liver: abdominal pain, diarrhea, dyspepsia, nausea, vomiting; in rare cases-flatulence, dry mouth, gastritis, esophagitis, formation of peptic ulcers and/or bleeding in the gastrointestinal tract (including rectal), stomatitis, glossitis, colitis, dysphagia, hepatitis, pancreatitis, liver function disorders.

Allergic reactions: possible skin rashes, hypersensitivity reactions accompanied by shortness of breath, tachycardia, bronchospasm, Stevens-Johnson syndrome, exfoliative dermatitis, angiitis, fever, allergic rhinitis, lymphadenopathy.

From the central nervous system: rarely-dizziness, headache, drowsiness, agitation, sleep disorders, tinnitus, hearing loss, dysarthria, hallucinations, migraine, peripheral neuropathy, syncopal states, aseptic meningitis.

From the sensory organs: visual impairment, conjunctivitis.

From the peripheral blood and coagulation system: rarely-leukopenia, thrombocytopenia.

From the side of metabolism: rarely-increased sweating, chills, changes in body weight.

From the cardiovascular system: rarely-arterial hypertension, tachycardia, peripheral edema.

From the urinary system: rarely-dysuria, in some cases-glomerulonephritis, papillary necrosis and nephrotic syndrome with transition to acute renal failure, interstitial nephritis, crystalluria, polyuria.

Interaction

Reduces the effectiveness of uricosuric drugs, increases the effect of anticoagulants, antiplatelet agents, fibrinolytics, side effects of MCS and corticosteroids, estrogens; reduces the effect of antihypertensive drugs and diuretics; increases the hypoglycemic effect of sulfonylurea derivatives.

Increases the concentration of Li+ and methotrexate in the blood. Reduces the renal clearance of digoxin. Cimetidine increases the concentration of lornoxicam in plasma.

Antacids and colestyramine reduce absorption. Myelotoxic drugs increase the manifestations of hematotoxicity of the drug.

How to take, course of administration and dosage

Xefocam tablets are taken orally, before meals, with a glass of water.

For moderate and severe pain: the recommended dose is 8-16 mg / day, divided into 2-3 doses; the maximum daily dose is 16 mg.

For inflammatory and degenerative rheumatic diseases: the recommended initial dose is 12 mg; the standard dose is 8-16 mg / day, depending on the patient’s condition.

The duration of therapy depends on the nature and course of the disease.

Overdose

Symptoms: increased side effects from the central nervous system and digestive system, acute renal failure.

Treatment: gastric lavage, activated charcoal, symptomatic therapy. Dialysis is ineffective.

Special instructions

During treatment, it is necessary to monitor the state of the gastrointestinal tract in order to prevent ulcerogenic effects or gastrointestinal bleeding.

Concomitant administration of omeprazole or H2-histamine receptor blockers, synthetic Pg analogues (misoprostol) can reduce the risk of ulcerogenic effects.

During treatment, it is necessary to monitor the picture of peripheral blood and the functional state of the liver and kidneys. In patients with renal insufficiency (plasma creatinine concentration 150-300 mmol/L), dosage adjustment and regular monitoring of renal function are required.

If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study. It retains Na+, K+, Li+ and water in the body, which can worsen the course of arterial hypertension and HF, and in people taking Li+ preparations, increase the severity of side effects of Li+salts. Elderly patients, as well as those with arterial hypertension, need regular blood pressure monitoring.

During the treatment period, care should be taken when driving vehicles and doing other activities. potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Form of production

Coated tablets.

Storage conditions

At a temperature of 15-25 °C

Shelf life

5 years

Active ingredient

Lornoxicam

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Weight

Weight: 19 gr.